GlassScriptPhysician profile
Valery N Lipenko
NPI 1982604427
$170,827.13
in general payments reported to CMS, 2019-2025
66 companies · $7,225 in 2025
The $7,225 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $62K · 2021: $48K · 2022: $12K · 2023: $6,398 · 2024: $11K · 2025: $7,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $6,010 · Travel and Lodging: $1,547 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,350.00 |
| Food and Beverage | $6,009.60 |
| Travel and Lodging | $1,546.81 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58,933.04 | 2019-2022 | |
| Abbvie INC. | $36,011.50 | 2021-2025 | |
| Amgen INC. | $24,946.99 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $15,623.80 | 2019-2024 | |
| Lilly USA, LLC | $11,379.36 | 2019-2025 | Kisunla, Zepbound, Reyvow |
| Biohaven Pharmaceuticals, INC. | $7,577.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $6,113.48 | 2022 | |
| Eisai INC. | $1,635.94 | 2020-2025 | |
| Livanova USA, INC. | $1,125.98 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $1,005.67 | 2023-2025 | Percept PC Brainsense, Inceptiv |
| Ucb, INC. | $819.84 | 2019-2024 | Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $782.63 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Pfizer INC. | $601.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $393.83 | 2019-2025 | |
| Biogen, INC. | $350.66 | 2019-2025 | Tysabri, Vumerity, Leqembi |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valery Lipenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.